(3S,5S)-Piperidine-1,3,5-tricarboxylic acid 1-tert-butyl ester 3-methyl ester | 595555-71-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: (3S,5S)-Piperidine-1,3,5-tricarboxylic acid 1-tert-butyl ester 3-methyl ester
• 英文别名: trans-1-[(Tert-butoxy)carbonyl]-5-(methoxycarbonyl)piperidine-3-carboxylic acid；(3S,5S)-5-methoxycarbonyl-1-[(2-methylpropan-2-yl)oxycarbonyl]piperidine-3-carboxylic acid
• CAS: 595555-71-8
• 化学式: C₁₃H₂₁NO₆
• 分子量: 287.313
• InChiKey: DYLHJFCOKNLATM-IUCAKERBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  20
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.77
• 拓扑面积：
  93.1
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  (3S,5S)-Piperidine-1,3,5-tricarboxylic acid 1-tert-butyl ester 3-methyl ester 、 C-[9-(4-methoxy-butyl)-9H-xanthen-9-yl]-methylamine 生成 (3S*,5S*)-5-{[9-(4-Methoxy-butyl)-9H-xanthen-9-ylmethyl]-carbamoyl}-piperidine-1,3-dicarboxylic acid 1-tert-butyl ester 3-methyl ester
  参考文献：
  名称：

  3-Mono-and 3,5-Disubstituted Piperidine Derivatives as Renin Inhibitors

  摘要：

  本发明涉及3,5-哌啶化合物，这些化合物用于诊断和治疗温血动物，特别是用于治疗依赖肾素活性的疾病(=紊乱)；该类化合物用于制备用于治疗依赖肾素活性疾病的制药配方；该类化合物用于治疗依赖肾素活性的疾病；包括3,5-哌啶化合物的制药配方和/或包括给予3,5-哌啶化合物的治疗方法，一种制备3,5-哌啶化合物的方法，以及其合成的新中间体和部分步骤。特别地，3,5-哌啶化合物具有式I，其中符号具有规范中描述的含义。

  公开号：

  US20080194629A1
• 作为产物：
  描述：

  1-tert-butyl 3,5-dimethyl piperidin-1,3,5-tricarboxylate 在 sodium hydroxide 、 pig liver esterase 、 sodium chloride 作用下， 以 甲醇 、 phosphate buffer 为溶剂， 反应 44.0h， 生成 (3S,5S)-Piperidine-1,3,5-tricarboxylic acid 1-tert-butyl ester 3-methyl ester
  参考文献：
  名称：

  Chemoenzymatic preparation of non-racemic N-Boc-piperidine-3,5-dicarboxylic acid 3-methyl esters and their 5-hydroxymethyl derivatives

  摘要：

  For the synthesis of (R,R)- and (S,S)-N-Boc-5-hydroxymethyl-piperidine-3-carboxylic acid methyl ester as important basic units for potential inhibitors of aspartyl proteases, the respective non-racemic 3,5-dicarboxylic acid monomethyl esters were prepared as key intermediates from a cis, trans -mixture of the respective diester by several consecutive enzymatic reactions using Lipase AY, Chirazyme L-3, Hydrolase ESP-ESL-1064 and pig liver esterase. (C) 2003 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0957-4166(03)00283-0

文献信息

• Organic Compounds
  申请人：Ehara Takeru

  公开号：US20090192148A1

  公开（公告）日：2009-07-30

  The invention relates to 3,5-substituted piperidine compounds, these compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (=disorder) that depends on activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; pharmaceutical formulations comprising a 3,5-substituted piperidine compound, and/or a method of treatment comprising administering a 3,5-substituted piperidine compound, a method for the manufacture of a 3,5-substituted piperidine compound, and novel intermediates and partial steps for its synthesis. The compounds have the formula I′ wherein R1, R2, T, R3 and R4 areas defined in the specification.

  本发明涉及3,5-取代哌啶化合物，这些化合物用于诊断和治疗温血动物，特别是用于治疗依赖肾素活性的疾病（=失调）；该类化合物用于制备治疗依赖肾素活性疾病的制剂；该类化合物用于治疗依赖肾素活性的疾病；包括3,5-取代哌啶化合物的制药配方和/或包括给予3,5-取代哌啶化合物的治疗方法，以及制造3,5-取代哌啶化合物的新型中间体和部分合成步骤。该化合物的式子为I'，其中R1、R2、T、R3和R4在规范中有定义。
• 3 , 5-substitued piperidine compounds as renin inhibitors
  申请人：Novartis AG

  公开号：EP2420491A1

  公开（公告）日：2012-02-22

  The invention relates to 3,5-substituted piperidine compounds, these compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (= disorder) that depends on activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; pharmaceutical formulations comprising a 3,5-substituted piperidine compound, and/or a method of treatment comprising administering a 3,5-substituted piperidine compound, a method for the manufacture of a 3, 5-substituted piperidine compound, and novel intermediates and partial steps for its synthesis. The compounds (which can also be present as salts) have the formula I' wherein R1, R2, T, R3, R4, R7 and R8 are as defined in the specification and R6 is OH.

  本发明涉及3,5-取代的哌啶化合物，这些化合物用于温血动物的诊断和治疗，特别是用于治疗依赖于肾素活性的疾病（=紊乱）；使用该类化合物制备药物制剂，用于治疗依赖于肾素活性的疾病；该类化合物在治疗依赖于肾素活性的疾病中的用途；包含 3,5-取代的哌啶化合物的药物制剂，和/或包括施用 3,5-取代的哌啶化合物的治疗方法，3,5-取代的哌啶化合物的制造方法，及其合成的新型中间体和部分步骤。 这些化合物（也可以以盐的形式存在）具有式 I' 其中 R1、R2、T、R3、R4、R7 和 R8 如说明书中所定义，R6 为 OH。
• 3 -M0N0- AND 3 , 5-DISUBSTITUTED PIPERIDINE DERIVATIVES AS RENIN INHIBITORS
  申请人：Novartis AG

  公开号：EP1879882A1

  公开（公告）日：2008-01-23
• US8129411B2
  申请人：——

  公开号：US8129411B2

  公开（公告）日：2012-03-06
• [EN] 3 -M0N0- AND 3 , 5-DISUBSTITUTED PIPERIDINE DERIVATIVES AS RENIN INHIBITORS<br/>[FR] DERIVES DE PIPERIDINE 3-MONO- ET 3,5-DISUBSTITUEE EN TANT QU'INHIBITEURS DE RENINE
  申请人：NOVARTIS AG

  公开号：WO2006117183A1

  公开（公告）日：2006-11-09

  [EN] The invention relates to 3,5-piperidine compounds, these compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (= disorder) that depends on activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; pharmaceutical formulations comprising a 3,5- piperidine compound, and/or a method of treatment comprising administering a 3,5- piperidine compound, a method for the manufacture of a 3,5-piperidine compound, and novel intermediates and partial steps for their synthesis. Especially, the 3,5-piperidine compounds have the formula I, wherein the symbols have the meanings described in the specification.
  [FR] L'invention concerne des composés de 3,5-pipéridine, lesdits composés étant destinés à être utilisés dans le diagnostic et le traitement thérapeutique d'un animal à sang chaud, notamment pour le traitement d'une maladie (trouble) qui dépend de l'activité de la rénine ; l'utilisation d'un composé de ladite classe pour la préparation d'une formulation pharmaceutique destinée au traitement d'une maladie qui dépend de l'activité de la rénine ; l'utilisation d'un composé de ladite classe dans le traitement d'une maladie qui dépend de l'activité de la rénine ; des formulations pharmaceutiques comprenant un composé de 3,5-pipéridine, et/ou une méthode de traitement consistant à administrer un composé de 3,5-pipéridine, une méthode de production d'un composé de 3,5-pipéridine, ainsi que de nouveaux intermédiaires et des étapes partielles pour leur synthèse. L'invention concerne notamment les composés de 3,5-pipéridine représentés par la formule I, les symboles présentant les significations définies dans la description.